Eptinezumab-jjmr - Medical Clinical Policy Bulletins

Initial and renewal requests for the medication listed in this policy are subject to site of care management

Most common adverse events included injection site pain, nausea, dizziness, injection site Eptinezumab-jjmr was approved in February 21, 2020

jjmrsite ACCESS: Access and maintain IV site or Port-A-Cath in accordance with the appropriate MYM OIC P&Ps TREATMENT REGIMEN: (another brand of drug, identical in

jjmr site Initial and renewal requests for the medication listed in this policy are subject to site of care management